Update information

Update information

November 2019: Recommendation 1.5.23 on the use of Sativex (a THC:CBD spray) to treat spasticity in people with MS has been replaced with a cross-reference to recommendations on THC:CBD spray in the NICE guideline on cannabis-based medicinal products.

July 2019: Because of a risk of abuse and dependence, gabapentin is controlled under the Misuse of Drugs Act 1971 as a class C substance and scheduled under the Misuse of Drugs Regulations 2001 as schedule 3 (as of 1 April 2019). A footnote in this guideline has been amended to reflect this change.

Minor changes since publication

November 2018: After a surveillance review, some recommendations have had links to other relevant NICE guidance added or updated, and some links to external sites have been updated.

ISBN: 978‑1‑4731‑0778‑6

  • National Institute for Health and Care Excellence (NICE)